Astera Labs chief executive officer Mohan Jitendra sold a total of 335,861 shares of the company's common stock in several transactions on April 17 and April 20, 2026, according to a Form 4 filing with the SEC. The aggregate proceeds from those disposals amounted to $57,852,785, with individual trade prices recorded between $167.29 and $176.05 per share.
The insider transactions were carried out under a Rule 10b5-1 trading plan that Mr. Jitendra established on December 1, 2025. All of the reported sales were executed indirectly through a living trust for which Jitendra serves as trustee.
Breakdown of the April 17 transactions
On April 17 the living trust sold multiple blocks of shares at varying weighted-average prices:
- 17,856 shares at a weighted average price of $167.95 (individual prices ranged from $167.29 to $168.28)
- 29,085 shares at a weighted average price of $168.78 (prices ranged from $168.29 to $169.25)
- 35,384 shares at a weighted average price of $169.80 (prices ranged from $169.29 to $170.28)
- 39,276 shares at a weighted average price of $170.77 (prices ranged from $170.29 to $171.28)
- 32,172 shares at a weighted average price of $171.81 (prices ranged from $171.29 to $172.28)
- 19,281 shares at a weighted average price of $172.67 (prices ranged from $172.29 to $173.28)
- 107,608 shares at a weighted average price of $174.06 (prices ranged from $173.29 to $174.28)
- 45,031 shares at a weighted average price of $174.43 (prices ranged from $174.2850 to $174.8900)
April 20 transactions
On April 20 the living trust completed two additional sales:
- 6,526 shares at a weighted average price of $175.24 (prices ranged from $174.5250 to $175.5100)
- 3,662 shares at a weighted average price of $175.81 (prices ranged from $175.5525 to $176.0500)
After these transactions the living trust continues to hold 4,069,134 shares of Astera Labs common stock. The filing also lists other indirect holdings attributed to Mr. Jitendra via estate planning vehicles: 699,999 shares by a Trust, 700,000 shares by 2021 Trust 1, 700,000 shares by 2021 Trust 2, 450,001 shares by 2022 Trust 1, and 450,001 shares by 2022 Trust 2. In addition, Mr. Jitendra directly owns 1,452,739 shares of common stock.
The insider sales come as Astera Labs shares have risen sharply over the prior 12 months, up 253%. The stock is trading at $192.02 and the company carries a market capitalization of $32.75 billion. An InvestingPro analysis cited in the filing indicates the share price appears overvalued relative to its Fair Value estimate, although the company retains a "GREAT" financial health score of 3.53 out of 5.
Recent financial performance and analyst coverage
Astera Labs reported strong fourth-quarter 2025 results, beating consensus expectations. The company posted adjusted earnings per share of $0.58, above the forecast of $0.51, and reported revenue of $270.6 million, a 92% year-over-year increase.
Following the quarterly report, RBC Capital raised its price target for Astera Labs to $250 and maintained an Outperform rating. RBC cited anticipated revenue associated with Trainium3-related Scorpio-X switch shipments starting in the third quarter of 2026 as a driver of upside.
By contrast, UBS initiated coverage with a neutral rating and a $180 price target. UBS analyst Natalia Winkler characterized Astera Labs as emerging as a credible supplier in AI networking, noting solid execution in retimers and successful expansion beyond its initial anchor customer, Amazon Web Services.
The filing and the company updates together provide a snapshot of insider liquidity, strong recent operating results, and differing analyst views on near-term valuation and growth prospects. The Form 4 filing confirms the mechanics of the sales and the post-transaction holdings, while the financial metrics and analyst notes add context to how the market and equity research community are positioning around Astera Labs as it scales into AI-focused networking opportunities.